The landscape of HIV treatment is on the precipice of a significant paradigm shift. For decades, the gold standard of care for people living with HIV (PLWH) has been a daily oral pill. However, data presented at the 26th International AIDS Conference has confirmed that an investigational once-weekly oral regimen—a collaboration between pharmaceutical giants Gilead Sciences and Merck—maintains robust virologic suppression in adults who have already achieved control over the virus.
The regimen combines 2 mg of Merck’s next-generation nucleoside reverse transcriptase translocation inhibitor (NRTTI), islatravir, with 300 mg of Gilead’s first-in-class capsid inhibitor, lenacapavir. By condensing the burden of treatment from seven pills a week to just one, this combination represents a potential landmark in patient-centered care. If it receives regulatory approval, it will become the first once-weekly oral maintenance therapy for adults with suppressed HIV, offering a middle ground between daily pills and long-acting injectable therapies.
The ISLEND Trials: Clinical Efficacy and Safety
The efficacy of the islatravir/lenacapavir (ISL/LEN) combination was solidified through the Phase 3 ISLEND-1 and ISLEND-2 trials. These trials enrolled a combined cohort of 1,209 adults who were already virologically suppressed on their existing antiretroviral therapy (ART).
ISLEND-1: The Double-Blind Benchmark
In the double-blind ISLEND-1 trial, researchers compared the weekly ISL/LEN regimen directly against the current market leader, Gilead’s daily single-tablet regimen, Biktarvy. The results were compelling: at Week 48, zero participants in the investigational arm experienced HIV-1 RNA levels at or above 50 copies/mL. By comparison, 0.3% of those who remained on the daily Biktarvy regimen met the threshold for virologic failure.
Safety profiles remained consistent across both groups. Treatment-related adverse events were reported in 13.5% of the ISL/LEN group and 13.2% of the Biktarvy group. Common side effects, such as nausea and headache, occurred in approximately 3% of the investigational group, demonstrating that the move to a weekly frequency does not inherently increase the toxicity burden on the patient.
ISLEND-2: Real-World Flexibility
ISLEND-2 provided a broader look at how the weekly regimen performs when patients transition from a variety of existing two- or three-drug regimens. As an open-label study, it offered insight into patient preference and "real-world" switching.
At the 48-week mark, 0.3% of ISL/LEN participants showed viral rebound (≥50 copies/mL) compared to 1.3% in the comparator arm. While treatment-related adverse events were slightly higher in the ISL/LEN arm (18% vs. <1%), investigators noted that this was likely a byproduct of the study design; patients in the standard-of-care arm were already long-term users of their medications, having moved past the initial "adjustment phase" where minor side effects are most common. Crucially, patient satisfaction metrics collected via the HIV Patient Perspective of Regimen Change instrument indicated that a clear majority of participants found the weekly regimen significantly less burdensome than their previous daily therapies.
A Chronology of Innovation
The path to the current ISLEND results has been carefully paved through iterative research and development.
- October 2024: Gilead and Merck announced promising Phase 2 data, showing that 104 virologically suppressed adults successfully maintained viral control when switching to the weekly ISL/LEN regimen. No participants experienced virologic failure, and mean adherence exceeded 98%.
- November 2024: During the HIV Glasgow conference, researchers addressed the critical challenge of "hepatitis B coverage." Because the ISL/LEN regimen does not contain tenofovir—a standard component of many HIV drugs that also treats hepatitis B—clinicians emphasized the necessity of ensuring patients are vaccinated against or screened for hepatitis B before switching.
- April 2026: The FDA approved Merck’s Idvynso (doravirine/islatravir), marking the first regulatory milestone for the islatravir molecule in a fixed-dose combination.
- June 2026: Gilead and Merck released topline findings from the Phase 3 ISLEND trials, confirming that the weekly oral combination met its primary endpoints.
- July 2026: Full, detailed results from ISLEND-1 and ISLEND-2 were formally presented at the 26th International AIDS Conference, triggering discussions regarding the future of the multi-billion-dollar HIV market.
The Science: Pharmacokinetics of Weekly Dosing
The ability to move from daily to weekly dosing is not a matter of simply increasing the dosage; it is the result of the distinct pharmacokinetic profiles of the two drugs involved.
Islatravir, Merck’s nucleoside analog, acts as a potent inhibitor of HIV-1 replication by stalling the reverse transcriptase enzyme through a process called translocation inhibition. Lenacapavir, Gilead’s capsid inhibitor, works by disrupting the HIV capsid, which is essential for the virus to complete its life cycle.
Because both drugs exhibit long half-lives in the body, they remain at therapeutic levels for extended periods. When paired, they provide a "pharmacokinetic safety net" that allows for a weekly dosing interval without sacrificing the efficacy required to keep viral loads suppressed. This represents a significant evolution from the early days of HIV treatment, where patients were required to take numerous pills multiple times a day to avoid resistance.
Implications for the HIV Treatment Market
The introduction of a weekly oral regimen creates a fascinating tension within the pharmaceutical industry, particularly for Gilead Sciences.
The Biktarvy Dominance
Gilead’s Biktarvy is currently the dominant force in the U.S. market, holding over 52% of the market share as of Q1 2026. In 2025 alone, the drug generated $14.3 billion in revenue. By introducing a weekly regimen that could potentially cannibalize its own blockbuster, Gilead is signaling a shift in strategy. The company appears to be prioritizing "treatment evolution"—moving patients to newer, more convenient, and potentially more patient-preferred regimens—to solidify long-term loyalty in an era where long-acting injectables from competitors are gaining traction.
Competitive Pressures: The Rise of Injectables
The primary competition for the weekly pill is not necessarily another pill, but the rapidly growing injectable market. ViiV Healthcare’s Cabenuva (cabotegravir and rilpivirine), which is administered every one or two months, has seen a 42% revenue increase. Injectables offer the "ultimate convenience" of fewer clinic visits, but they require professional administration.
The ISL/LEN regimen fills a vital gap. For patients who are needle-phobic or prefer the autonomy of self-administering their treatment at home, a once-weekly pill provides the freedom of a long-acting regimen without the necessity of frequent visits to a medical facility.
Strategic Considerations for Clinicians
As the medical community reviews these findings, the conversation has moved beyond simple efficacy to the practicalities of implementation. The lack of hepatitis B protection in the ISL/LEN regimen remains a point of clinical focus. As Dr. Amy Colson and her colleagues have noted, moving away from tenofovir-based regimens requires a robust public health strategy, including aggressive hepatitis B vaccination programs for HIV patients.
Looking Ahead
The success of the ISLEND trials suggests that the era of "one-size-fits-all" daily therapy is drawing to a close. For the millions of people living with HIV, the prospect of taking 52 pills a year instead of 365 is more than just a convenience—it is a significant reduction in the daily psychological reminder of their diagnosis.
As Gilead and Merck prepare for regulatory submissions, the broader HIV care community is already preparing for the logistical and clinical changes this will bring. With additional research, such as Gilead’s ongoing trials for a daily bictegravir/lenacapavir regimen, the portfolio of options for patients is growing more diverse, more flexible, and more tailored to the individual needs of those living with HIV.
The transition to a once-weekly oral regimen is poised to be one of the most significant advancements in HIV care in the last decade, proving that through sophisticated drug design and rigorous clinical investigation, the burden of chronic disease management can be substantially lightened.
About the Author
